258 related articles for article (PubMed ID: 29631510)
21. Effects of thyrotropin and thyrotropin-receptor-stimulating Graves' disease immunoglobulin G on cyclic adenosine monophosphate and hyaluronan production in nondifferentiated orbital fibroblasts of Graves' ophthalmopathy patients.
van Zeijl CJ; Fliers E; van Koppen CJ; Surovtseva OV; de Gooyer ME; Mourits MP; Wiersinga WM; Miltenburg AM; Boelen A
Thyroid; 2010 May; 20(5):535-44. PubMed ID: 20384487
[TBL] [Abstract][Full Text] [Related]
22. A review of TSHR- and IGF-1R-related pathogenesis and treatment of Graves' orbitopathy.
Cui X; Wang F; Liu C
Front Immunol; 2023; 14():1062045. PubMed ID: 36742308
[TBL] [Abstract][Full Text] [Related]
23. TSH/IGF1 receptor crosstalk: Mechanism and clinical implications.
Krieger CC; Neumann S; Gershengorn MC
Pharmacol Ther; 2020 May; 209():107502. PubMed ID: 32061922
[TBL] [Abstract][Full Text] [Related]
24. Graves' Autoantibodies Exhibit Different Stimulating Activities in Cultures of Thyrocytes and Orbital Fibroblasts Not Reflected by Clinical Assays.
Krieger CC; Kahaly GJ; Azam A; Klubo-Gwiezdzinska J; Neumann S; Gershengorn MC
Thyroid; 2022 Jan; 32(1):90-96. PubMed ID: 34714162
[No Abstract] [Full Text] [Related]
25. Circulating IgGs may modulate IGF-I receptor stimulating activity in a subset of patients with Graves' ophthalmopathy.
Varewijck AJ; Boelen A; Lamberts SW; Fliers E; Hofland LJ; Wiersinga WM; Janssen JA
J Clin Endocrinol Metab; 2013 Feb; 98(2):769-76. PubMed ID: 23295466
[TBL] [Abstract][Full Text] [Related]
26. Current Insights into the Pathogenesis of Graves' Ophthalmopathy.
Bahn RS
Horm Metab Res; 2015 Sep; 47(10):773-8. PubMed ID: 26361262
[TBL] [Abstract][Full Text] [Related]
27. Thyrotropin and Insulin-Like Growth Factor 1 Receptor Crosstalk Upregulates Sodium-Iodide Symporter Expression in Primary Cultures of Human Thyrocytes.
Morgan SJ; Neumann S; Marcus-Samuels B; Gershengorn MC
Thyroid; 2016 Dec; 26(12):1794-1803. PubMed ID: 27638195
[TBL] [Abstract][Full Text] [Related]
28. A stimulatory TSH receptor antibody enhances adipogenesis via phosphoinositide 3-kinase activation in orbital preadipocytes from patients with Graves' ophthalmopathy.
Kumar S; Nadeem S; Stan MN; Coenen M; Bahn RS
J Mol Endocrinol; 2011 Jun; 46(3):155-63. PubMed ID: 21321093
[TBL] [Abstract][Full Text] [Related]
29. Cutting edge: retrobulbar inflammation, adipogenesis, and acute orbital congestion in a preclinical female mouse model of Graves' orbitopathy induced by thyrotropin receptor plasmid-in vivo electroporation.
Moshkelgosha S; So PW; Deasy N; Diaz-Cano S; Banga JP
Endocrinology; 2013 Sep; 154(9):3008-15. PubMed ID: 23900776
[TBL] [Abstract][Full Text] [Related]
30. TSH-Mediated TNFα Production in Human Fibrocytes Is Inhibited by Teprotumumab, an IGF-1R Antagonist.
Chen H; Shan SJ; Mester T; Wei YH; Douglas RS
PLoS One; 2015; 10(6):e0130322. PubMed ID: 26087256
[TBL] [Abstract][Full Text] [Related]
31. Pathogenesis of Graves' ophthalmopathy: the role of autoantibodies.
Khoo TK; Bahn RS
Thyroid; 2007 Oct; 17(10):1013-8. PubMed ID: 17935483
[TBL] [Abstract][Full Text] [Related]
32. Orbital Signaling in Graves' Orbitopathy.
Draman MS; Zhang L; Dayan C; Ludgate M
Front Endocrinol (Lausanne); 2021; 12():739994. PubMed ID: 34899596
[TBL] [Abstract][Full Text] [Related]
33. Pathogenic Phenotype of Adipogenesis and Hyaluronan in Orbital Fibroblasts From Female Graves' Orbitopathy Mouse Model.
Görtz GE; Moshkelgosha S; Jesenek C; Edelmann B; Horstmann M; Banga JP; Eckstein A; Berchner-Pfannschmidt U
Endocrinology; 2016 Oct; 157(10):3771-3778. PubMed ID: 27552248
[TBL] [Abstract][Full Text] [Related]
34. Thyrotropin receptor expression in Graves' orbital adipose/connective tissues: potential autoantigen in Graves' ophthalmopathy.
Bahn RS; Dutton CM; Natt N; Joba W; Spitzweg C; Heufelder AE
J Clin Endocrinol Metab; 1998 Mar; 83(3):998-1002. PubMed ID: 9506762
[TBL] [Abstract][Full Text] [Related]
35. Pathogenesis of graves ophthalmopathy: implications for prediction, prevention, and treatment.
Garrity JA; Bahn RS
Am J Ophthalmol; 2006 Jul; 142(1):147-153. PubMed ID: 16815265
[TBL] [Abstract][Full Text] [Related]
36. Potential involvement of the bone marrow in experimental Graves' disease and thyroid eye disease.
Gulbins A; Horstmann M; Keitsch S; Soddemann M; Wilker B; Wilson GC; Zeidan R; Hammer GD; Daser A; Bechrakis NE; Görtz GE; Eckstein A
Front Endocrinol (Lausanne); 2023; 14():1252727. PubMed ID: 37810891
[TBL] [Abstract][Full Text] [Related]
37. Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves' disease and Graves' orbitopathy.
Marinò M; Rotondo Dottore G; Ionni I; Lanzolla G; Sabini E; Ricci D; Sframeli A; Mazzi B; Menconi F; Latrofa F; Vitti P; Marcocci C; Chiovato L
J Endocrinol Invest; 2019 Apr; 42(4):471-480. PubMed ID: 30132285
[TBL] [Abstract][Full Text] [Related]
38. Insulin-Like Growth Factor Pathway and the Thyroid.
Smith TJ
Front Endocrinol (Lausanne); 2021; 12():653627. PubMed ID: 34149612
[TBL] [Abstract][Full Text] [Related]
39. Modulating TSH Receptor Signaling for Therapeutic Benefit.
Krause G; Eckstein A; Schülein R
Eur Thyroid J; 2020 Dec; 9(Suppl 1):66-77. PubMed ID: 33511087
[TBL] [Abstract][Full Text] [Related]
40. A stimulatory thyrotropin receptor antibody enhances hyaluronic acid synthesis in graves' orbital fibroblasts: inhibition by an IGF-I receptor blocking antibody.
Kumar S; Iyer S; Bauer H; Coenen M; Bahn RS
J Clin Endocrinol Metab; 2012 May; 97(5):1681-7. PubMed ID: 22399503
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
